Clinical Trials Browser

Urinary Bladder Neoplasms × Cisplatin × 90 days × Clear all

NCT03775265 2026-03-18

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT06770582 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07106762 2026-03-10

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT07129993 2026-03-05

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06960577 2026-02-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06225596 2026-02-17

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03661320 2026-02-03

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT07097142 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT02690558 2026-01-28

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Active not recruiting

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell